Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
A review of ranibizumab clinical trial data in exudative age-related macular degeneration and how to translate it into daily practice Mones JOphthalmologica 2011[]; 225 (2): 112-9The results of randomized controlled clinical trials of ranibizumab for the treatment of age-related macular degeneration established a new standard of care with the prospect of improved vision in many patients. Subsequent trials have explored different strategies to increase response rates and reduce treatment frequency. This review analyzes the key clinical trial data for ranibizumab on the basis of which the author proposes a new treatment regimen with the aim of rationalizing treatment frequency without compromising improvements in vision--the FUSION regimen. This consists of an initiation phase followed by pro re nata (PRN) retreatment combined with fixed injections after a period of disease inactivity of 2-4 months (depending on the time elapsed since the last injection). A randomized clinical trial is recommended for comparing monthly, PRN and the FUSION regimens.|Angiogenesis Inhibitors/*administration & dosage[MESH]|Antibodies, Monoclonal, Humanized[MESH]|Antibodies, Monoclonal/*administration & dosage[MESH]|Exudates and Transudates[MESH]|Humans[MESH]|Intravitreal Injections[MESH]|Macular Degeneration/*drug therapy/physiopathology[MESH]|Randomized Controlled Trials as Topic[MESH]|Ranibizumab[MESH]|Retreatment[MESH]|Treatment Outcome[MESH]|Vascular Endothelial Growth Factor A/antagonists & inhibitors[MESH]|Visual Acuity/physiology[MESH] |
